IMPORTANT UPDATES

Robert F Sidonio, Jr, MD

Pediatric Hematologist/Oncologist

Gender
Male
Language
English

Primary Specialty

Hematology/Oncology


Leadership Titles

Clinical Director, Hemostasis/Thrombosis


Education

Board Certification
Am Bd Pediatrics (Sub: Pediatric Hematology-Oncology)
Medical School:
University of Alabama at Birmingham
Residency:
University of Louisville School of Medicine
Fellowship:
University of Pittsburgh Medical Center

Publications

Pubmed Profile

Network


Introduction

Dr. Sidonio is a Pediatric Hematologist/Oncologist at the Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta and Associate Professor of Pediatrics at Emory University School of Medicine. He currently serves as Clinical Director of the Hemostasis and Thrombosis Program at Children’s.

Dr. Sidonio attended medical school at the University of Alabama at Birmingham School of Medicine and completed his residency at the University of Louisville/Kosair Children’s Hospital in Louisville, Kentucky. He was a fellow at the University of Pittsburgh Medical Center/Children’s Hospital of Pittsburgh, where he also received his Master of Science in clinical research.

Dr. Sidonio and his wife live in Atlanta with their two young boys.

Research

Dr. Sidonio’s research interests include bleeding phenotype of Hemophilia A and B carriers, Hemophilia A inhibitors and novel immune tolerance regimens, women with low von Willebrand factor, and Von Willebrand disease (ATHN 9).

Learn more about Dr. Sidonio’s research.

Focus of Practice

  • Hematology
  • Hemostasis and thrombosis

Areas of Interest

  • Von Willebrand disease
  • Hemophilia A and B
  • Low von Willebrand factor and von Willebrand disease
  • Rare bleeding disorders
  • Adolescent girls and women with bleeding disorders

Locations

Aflac Cancer and Blood Disorders Center

Egleston Hospital, 1405 Clifton Road NE Atlanta, GA 30322 Get Directions 404-785-1112

In the News

Georgia Four-year Old Tests New Drug to Prevent Bleeding

A patient at the Aflac Cancer and Blood Disorders Center was the first child to receive a drug designed to reduce the number of dangerous bleeding episodes in hemophiliacs.


Fox 5